Core Viewpoint - The strategic partnership between MIRXES-B and N Health aims to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and improving patient outcomes in the region [1][2]. Group 1: Strategic Partnership - The partnership is established to leverage MIRXES-B's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer [2]. - The collaboration will introduce cancer screening tests across nearly 60 hospitals within the N Health network, supporting broader access to early disease detection services in Thailand and Southeast Asia [2]. - N Health aims to enhance its role in providing end-to-end healthcare solutions and expand the accessibility of advanced cancer screening nationwide, integrating cancer risk assessments into preventive care [2]. Group 2: Market Potential - Thailand's health check-up market is projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1]. - The increasing awareness of preventive healthcare and rising chronic disease prevalence create an ideal environment for adopting innovative diagnostic technologies like MIRXES-B's miRNA tests [1]. Group 3: New Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3]. - These home test kits are designed to complement the core miRNA cancer screening solutions and are the first of their kind in the Thai market, featuring an innovative single-device design that minimizes processing steps and reduces contamination risks [3][4]. - The distribution of these test kits will be through modern trade and pharmacy channels across Thailand, aligning with evolving consumer healthcare behaviors and increasing demand for preventive, self-diagnostic solutions [4].

Group 1 - MIRXES-B has established a strategic partnership with N Health to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step in early cancer detection and improving patient outcomes in the region [1] - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1] - The partnership aims to leverage the increasing awareness of preventive healthcare and the rising prevalence of chronic diseases to create an ideal environment for adopting innovative diagnostic technologies like miRNA testing [1] Group 2 - The company launched a new series of home screening test kits in Thailand, including HELICORapid for detecting H. pylori infections and FITRapid for detecting fecal occult blood, both of which are significant cancer risk factors [2] - These home testing kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into a streamlined component, reducing processing steps and minimizing contamination risks [2] - The company aims to expand its sales and marketing efforts into the consumer sector, providing easy-to-use and hygienic home testing options while maintaining scientific rigor and user safety [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 自願性公告 於泰國的近期業務發展進程 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 與N HEALTH建立戰略夥伴關係 本公司董事（「董事」）會（「董事會」）宣佈，本公司已於2025年12月15日與N Health （「N Health」，為 一 家 醫 療 保 健 解 決 方 案 供 應 商 及 泰 國 最 大 醫 療 保 健 供 應 商 Bangkok Dusit Medical Services (BDMS) Group的成員公司）建立戰略夥伴關係（「戰 略夥伴關係」）。戰略夥伴關係旨在將先進的microRN ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02629 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.00001 USD | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.00001 USD | | 100,000 | 本月底法定/註冊股本總額： USD 100,000 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Mirxes Holding Company Limited (於 ...

Core Viewpoint - The "Annual Excellence in Innovation IPO" award recognizes companies that have demonstrated significant achievements in product, model, and organizational innovation over the past year, highlighting their ability to keep pace with market trends through continuous innovation [4]. Group 1: Award Recipients - Six companies were awarded the "Annual Excellence in Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yino Pharma (02591.HK), Yunhan Chip City (301563.SZ), Yunjing (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the awarded companies is not in any specific order and is based on the first letter of their names [1]. Group 2: Evaluation Criteria - The evaluation for the award was based on quantitative data analysis and assessments from an expert review panel [4]. - The award aims to create a valuable reference list of listed companies and unicorns within the investment community, covering all companies listed on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

Core Viewpoint - The "Golden Award" annual excellence company selection by Gelonghui recognizes innovative companies in the IPO sector, highlighting their achievements in product, model, and organizational innovation over the past year [1][2]. Group 1: Award Winners - Six companies received the "Annual Excellence Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yinnuo Pharmaceutical-B (02591.HK), Yunhan Chip City (301563.SZ), Yunjin (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the award winners is not in any particular order and is based on the first letter of the company names [1]. Group 2: Evaluation Criteria - The award evaluates companies based on quantitative data analysis and expert review, focusing on their innovation in products, business models, and organizational structures [1]. - The aim of the selection is to recognize new listed companies that have achieved excellent results through continuous innovation and alignment with market trends [1]. Group 3: Scope of the Selection - The "Golden Award" selection covers all listed companies and unicorns on major stock exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [2]. - The initiative is driven by the vision of providing valuable references for investors regarding listed companies and unicorns in the market [2].

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The strategic collaboration between Mirxes and Jingtai Technology aims to integrate their strengths in early cancer detection and drug development, creating a comprehensive "diagnosis and treatment integration" solution for high-incidence cancers in Asia [1] Collaboration Model - The partnership focuses on building a closed-loop ecosystem of "detection + research" [2] - Mirxes will act as a "frontline detection and risk assessment expert" utilizing its leading position in blood-based miRNA cancer screening [3] - Jingtai Technology will serve as an "intelligent drug discovery engine" leveraging quantum physics, AI, and robotic experimentation [3] - Both companies plan to create a disease database focused on the Asian population to drive the discovery of new diagnostic markers and therapeutic targets [3] Strategic Intent - This collaboration signifies Mirxes' strategic shift from solely "early diagnosis" to a broader "diagnosis and treatment integration" approach [4] - By closely aligning with upstream drug development platforms, the company aims to participate in higher-value treatment segments, enhancing its competitive barriers and customer loyalty [5] Fundamental Support - Mirxes' strategic advancement is backed by improving fundamentals [6] - Recent business expansions include inclusion in the Hang Seng Composite Index, endorsement from Malaysia's sovereign fund, and obtaining key market access qualifications [7] - The company reported a revenue of $10.5 million in the first half of the year, with core early screening business revenue growing by 50% year-over-year [7] - Gross margin improved significantly from 49% to 67.6%, indicating strong product capability and cost control [7] - Cash reserves reached $108 million, providing financial flexibility for R&D collaboration and market expansion [7] Investment Perspective - Mirxes currently exhibits strong growth in core business and a clear long-term strategy [8] - Short-term certainty is based on the commercial progress of its gastric cancer screening and the effectiveness of its high-margin business model [9] - Long-term potential is enhanced by collaborations with major players like Watson and Jingtai, which open avenues for extending from diagnostic data to treatment [9] Conclusion - The strategic partnership between Mirxes and Jingtai Technology represents a forward-looking move to break through the limitations of the early screening industry and tap into the larger precision medicine market [11] - The company is at a critical juncture of "performance realization" and "model transition," necessitating attention to both existing business growth and the potential value creation from the new ecosystem [12]

谅解备忘录项下的合作符合公司与晶泰科技推进早期检测、早期干预以协助每个人活出健康生活的长期 目标，预示着公司从早期检测延伸到早期干预及精准医疗的重要拓展。透过发挥公司与晶泰科技的互补 优势，此项合作将创造协同效应，结合公司积累多年的高质量癌症生物组学数据、其在癌症诊断领域构 建的资源，及在亚太区域的运营优势，以及晶泰科技在生物医药领域深耕多年的AI研发平台、在药物 研发╱消费健康方面的研发经验，以及其多年构建的生物医药大数据收集、清洗、开发的能力，继而共 同研究与产业化一个AI赋能的、创新的，针对亚洲高发癌种，特别是消化道癌的早诊早治解决方案。 MIRXES-B(02629)发布公告，公司近期与晶泰控股有限公司(晶泰科技)订立了一份谅解备忘录，据此， 双方同意整合公司在基因组学技术及其庞大的、以亚洲人群为中心的疾病数据库方面的核心优势，与晶 泰科技领先的AI+机器人的药物发现和研究平台，针对亚洲高发癌种，特别是消化道癌的早期发现与干 预，共建一个AI赋能的、创新的"诊疗一体化"研究及产业化平台，结合诊断与治疗，合作开发早诊早治 解决方案。谅解备忘录自签署之日起生效，有效期为两年，自签署之日起算。 ...

Core Viewpoint - MIRXES-B has signed a memorandum of understanding with Crystal Technology to integrate genomic technology and a disease database focused on Asian populations with AI-driven drug discovery and research platforms, aiming to develop early detection and intervention solutions for prevalent cancers in Asia, particularly gastrointestinal cancers [1][2] Group 1 - The collaboration aligns with the long-term goal of promoting early detection and intervention to assist individuals in leading healthier lives [2] - This partnership signifies an important expansion from early detection to early intervention and precision medicine for the company [2] - The collaboration aims to create synergies by leveraging the complementary strengths of both companies, including high-quality cancer biomarker data and operational advantages in the Asia-Pacific region [2] Group 2 - Crystal Technology brings years of experience in AI research and development in biomedicine, along with capabilities in data collection, cleaning, and development in the biopharmaceutical sector [2] - The joint effort will focus on researching and industrializing AI-enabled innovative solutions for early diagnosis and treatment of high-incidence cancers in Asia [2]